Physician profile
Connie Ward
NPI 1407140569
$4,547.51
in general payments reported to CMS, 2019-2025
47 companies · $1,239 in 2025
The $1,239 reported for 2025 was more than what 88% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $576 · 2022: $1,388 · 2023: $202 · 2024: $1,143 · 2025: $1,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,396 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,395.86 |
| Education | $187.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $624.15 | 2021-2025 | Andexxa, Lynparza, Enhertu |
| Janssen Biotech, INC. | $402.31 | 2021-2025 | Rybrevant, Imbruvica, Darzalex |
| Merck Sharp & Dohme LLC | $305.65 | 2022-2025 | Keytruda, Lynparza |
| Lilly USA, LLC | $282.68 | 2021-2025 | Verzenio |
| Seagen INC. | $259.35 | 2021-2022 | |
| Incyte Corporation | $256.09 | 2024-2025 | Jakafi, Jakafi, Monjuvi |
| Novartis Pharmaceuticals Corporation | $237.56 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $227.36 | 2021-2025 | Libtayo |
| Celgene Corporation | $154.28 | 2022-2025 | Reblozyl |
| Pfizer INC. | $146.50 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $119.77 | 2022-2024 | Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $115.44 | 2024-2025 | Fruzaqla |
| Daiichi Sankyo INC. | $109.46 | 2022-2025 | Enhertu, Vanflyta |
| Genentech USA, INC. | $103.68 | 2024-2025 | Polivy, Venclexta, Tecentriq |
| Eisai INC. | $89.58 | 2022-2025 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Connie Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.